An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT ID: NCT01833039
Last Updated: 2025-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
NCT01779791
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT02169180
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT01325701
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01776840
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT02446236
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibrutinib
Ibrutinib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients previously treated with ibrutinib are not eligible.
* Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmacyclics LLC.
INDUSTRY
Janssen Biotech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Duarte, California, United States
Los Angeles, California, United States
Stanford, California, United States
Denver, Colorado, United States
Norwalk, Connecticut, United States
Stamford, Connecticut, United States
Washington D.C., District of Columbia, United States
Miami Beach, Florida, United States
Ocala, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Goshen, Indiana, United States
Sioux City, Iowa, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Metairie, Louisiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
Jefferson City, Missouri, United States
St Louis, Missouri, United States
Lincoln, Nebraska, United States
Omaha, Nebraska, United States
Reno, Nevada, United States
Hackensack, New Jersey, United States
New Hyde Park, New York, United States
New York, New York, United States
Syracuse, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Watertown, South Dakota, United States
Knoxville, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Burlington, Vermont, United States
Morgantown, West Virginia, United States
Barretos, , Brazil
Florianópolis, , Brazil
Porto Alegre, , Brazil
Rio de Janeiro, , Brazil
Salvador, , Brazil
São Paulo, , Brazil
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCI-32765MCL4001
Identifier Type: OTHER
Identifier Source: secondary_id
CR101862
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.